research Review of Promising Off-Label Use of Deucravacitinib
Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
Search
for
Sort by
Research
480-510 / 1000+ resultsresearch LB708 ILC1-like innate lymphocytes in human autoimmunity: Lessons from Alopecia Areata
ILC1-like cells can cause alopecia areata by disrupting hair follicle immunity, suggesting a new treatment approach.
research ANTI-CD19 MONOCLONAL ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROMYELITIS OPTICA SPECTRUM DISORDER
Anti-CD19 therapy may help treat SLE and NMOSD.
research 332 OTULIN maintains skin homeostasis by controlling keratinocyte death and stem cell identity
ILC1-like cells can cause alopecia areata by affecting hair follicles.
research Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
research Contents
The document concludes that new treatments for skin conditions are complex but effective, including spironolactone for female hair loss and propranolol for infantile hemangiomas.
research Skin manifestations associated with systemic diseases – Part II
Certain skin symptoms can indicate underlying body-wide illnesses.
research Immunohistochemical analysis of T-cell subsets in the inflammatory infiltrates of alopecia areata and its comparison with androgenetic alopecia
T-cell patterns in skin help distinguish alopecia areata from androgenetic alopecia.
research Evaluation of Serum Inflammatory Markers and Their Relationship to Treatment Response in Alopecia Areata Patients
SII is a useful and affordable tool to assess and monitor alopecia areata.
research A clinical study of pemphigus vulgaris and its variants, evaluation of safety and efficacy of glucocorticoids versus immunosuppressants at tertiary care hospital: a study of 75 cases
Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.
research PO.8.170 Drug-induced lupus or systemic lupus erythematosus after experimental COVID-19 therapy: difficulties in differential diagnosis
Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
research 13. Wound Healing & Hair
Certain drugs can cause lupus, stopping these drugs is the main treatment. NB-UVB phototherapy clears psoriasis faster when applied three times a week. Monoclonal antibodies and oral pimecrolimus are effective in treating psoriasis. Smoking and drinking are linked to psoriasis in men. No direct link between low iron and hair loss was found. Vaccines are effective against genital herpes and human papillomavirus type 16.
research Abstracts
The document concludes that misdiagnosis in skin conditions is common, certain treatments can cause allergic reactions, and some skin symptoms are linked to leukemia, especially in certain Japanese regions.
research Microneedle‐mediated Delivery of Immunomodulators Restores Immune Privilege in Hair Follicles and Reverses Immune‐Mediated Alopecia
A microneedle patch can help regrow hair by restoring immune balance in hair follicles.
research Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis
Topical immunotherapy can help with severe hair loss, but results vary and need personalized, long-term treatment.
research VITILIGO: WHAT’S OLD, WHAT’S NEW?
Vitiligo treatments are improving but relapses are common.
research Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients
APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.
research A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
Interferon and ribavirin can cause serious skin reactions and other health issues.
research Dermatologic therapy: December 1987 to December 1988
New skin treatments in 1987-1988 showed effectiveness for various conditions, but some had side effects or risks.
research Rare and common manifestations of COVID‐19 in children
COVID-19 can cause various skin issues in children, mostly not severe, with chilblain-like lesions being common, especially in adolescents.
research COVID-19 infection leading to acute pustular dermatoses
COVID-19 can directly trigger certain skin conditions like pustular dermatoses due to an inflammatory response.
research Infliximab as First‐Line Therapy in Severe Pediatric Crohn Disease
Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research Psoriasis in the limelight: the remarkable career of an old skin disease
Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
research 177 Chronic graft-versus-host disease exhibits distinct Th1-skewing and barrier abnormalities in the skin
Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.
research Comparative investigation of immune-related biomarkers related to alopecia areata subtypes
Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
research Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
research Common Topical Medications
The document concludes that various topical medications are effective for skin conditions but often cause skin irritation as a side effect.
research Alopecia areata: from pathophysiology to therapeutic innovation
JAK inhibitors are effective treatments for alopecia areata.
research An unusual presentation of dermatomyositis: The type Wong variant revisited
A woman with a rare type of dermatomyositis improved with low-dose prednisone and methotrexate.